Dossier assessment
Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)
-
Dossier assessment
Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)
Dossier assessment
Adult patients with type 2 diabetes mellitus with inadequate glycaemic control by diet and exercise plus metformin monotherapy
Comparison with sulfonylurea (glibenclamide or glimepiride) + metformin: hint of non-quantifiable (at most considerable) added benefit. Comparison with glipizide + metformin: treatment goal near-normal blood glucose levels: hint of considerable added benefit; other treatment goal: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.
Project details
- Project no.
- A18-65
- Commission
- Commission awarded on 28.09.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Sitagliptin - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Sitagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed